CRISPR Therapeutics downgraded by TD Cowen with a new price target
$CRSP
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
TD Cowen downgraded CRISPR Therapeutics from Market Perform to Underperform and set a new price target of $30.00